Milestones

• 2001

  CordLife Pte Ltd established and licensed by Ministry of Health (MOH) Singapore

• 2002

  First cord blood released for sibling-use.

  Laboratory at Camden Medical Centre opened for public viewing.

• 2005

  Received accreditation from American Association of Blood Banks (AABB)

  AABB's Accreditation Program strives to improve the quality and safety of collecting, processing, testing, distributing and administering blood and blood products by assessing the quality and operational systems in place within the facility.

  Offered Medicord, a stem cell transplant insurance programme.

  Entered Hong Kong and People's Republic of China (PRC) markets.

• 2007

  Expanded to new Science Park II facility.

  Cordlife Hong Kong achieved ISO:9001.

• 2008

  Re-accredited by American Association of Blood Banks (AABB).

  Launch of automated processing system to maximise recovery of cells for transplant use.

• 2009

  Re-accredited by American Association of Blood Banks (AABB).

  First-ever release of autologous cord blood for Cerebral Palsy

  Launched Cordlife Quality Guarantee, a warranty to protect Cordlife clients.

  Launched Cordlife Circle, a members-only benefit programme.

  Launched Preferential Plan upgrades for clients.

• 2010

  First-ever release of autologous cord blood for Neuroblastoma.

  Released autologous cord blood for Cerebral Palsy.

  Celebrated enrolment of our 25,000th client.

  Celebrated 10 years of quality cord blood banking.

• 2011

  CordLife Pte Ltd renamed to "Cordlife Group Limited".

  Launched Cordlife Care360° Safeguard programme.

  Re-accredited by American Association of Blood Banks (AABB).

  Launched provision of umbilical cord tissue banking services in Hong Kong.

  Hong Kong facility accredited by American Association of Blood Banks (AABB)

• 2012

  Successfully listed on Singapore Exchange Main Board on 29 March 2012.

  More than 40,000 clients stored their precious stem cells with Cordlife.

• 2013

  Cordlife Group Limited moved to its fully owned, 23,000sqft office and laboratory facility in A'Posh Bizhub, Yishun. The facility is capable of storing up to 650,000 cord blood units.

  First private cord blood bank in Singapore to launch automated processing system to facilitate the optimisation of cord blood stem cells for maximum transplant success*.

  Re-accredited by American Association of Blood Banks (AABB).

  Launched provision of umbilical cord lining banking services in Singapore with patented technology, CellOptima^™ that is exclusively available at Cordlife capable of isolating EpSCs and MSCs, two types of stem cells present in the umbilical cord.

  Awarded 'Most Transparent Company Award' by SIAS Investors Choice

• 2014

  Processed and stored over 45,000 cord blood units as of 21 March 2014.

  Collaborated with Make-A-Wish Foundation® (Singapore) Ltd granting the wishes of children with life-threatening medical conditions to enrich the human experience with hope, strength and joy.

  Enhanced Cordlife Pledge:360° assures quality processing and storage standards.

• 2015

  Received accreditation from FACT which ensures the global standard of excellence in patient care and laboratory practices.

  Cordlife is one out of the six private cord blood banks worldwide that is double-accredited and the first in Southeast Asia to achieve the dual-accreditation status with AABB and FACT (The Foundation for the Accreditation of Cellular Therapy).

  Launched the Cordlife-Jalan Kayu Pre-School Headstart Fund with a sponsorship of $150K to give young children from low-income families a chance in pre-school education.

  Partnered with autism and epilepsy treatment pioneer, Dr Michael Chez from Sutter Medical Group and Sutter Neuroscience Institute in the continued study of autologous cord blood cells treatments.

  Received the 16th SIAS Investors Choice Award (Runnerup), Singapore Corporate Governance Award (SCGA) 2015, Mid and Small Category

  Honoured by Forbes Asia as one of the "Best Under a Billion" companies in November 2015.

  Acquired the first and largest cord blood bank in Malaysia, Stemlife Berhad as one of its subsidiaries.

• 2016

  First Singapore-based cord blood bank to launch in Myanmar and Vietnam.

  Received Accreditation from College of American Pathologists for its Hong Kong and India Subsidiaries.

  Launched Cordlife’s inaugural "Cordlife Donation Drive" in Singapore and raised donations-in-kind for Children’s Aid Society – Melrose Home.

• 2017

  First cord blood bank in the Philippines to be AABB-accredited.

  More than 56,000 parents stored their child's precious stem cells with Cordlife.

  Launched NICE^®, a clinically approved non-invasive prenatal test in Indonesia and Philippines.

  Launched Cordlife’s first-ever public "Cordlife Donation Drive" in Singapore and raised both cash and donations-in-kind for Singapore Children’s Society.

• 2018

  Awarded "Best Family Cord Blood Bank Award" by Mummys Market.

  More than 60,000 parents stored their child’s precious stem cells with Cordlife.

• 2019

  Healthbaby Hong Kong’s facility became the first and only private cord blood bank in the country to receive FACT accreditation.

  Officially opened the largest full-fledged cord blood and tissue banking facility in Indonesia.

  Appointed marketing agent in Bangladesh, one of the fastest growing economies of the world.

  Cordlife Philippines received re-accreditation from AABB and remains the only AABB accredited facility in the country.

  Cordlife Indonesia’s facility became the first and only in Indonesia to receive AABB accreditation.

• 2020

  Cordlife Indonesia launched PreImplantation Genetic Screening to help improve the likelihood of a successful pregnancy of couples undergoing in vitro fertilisation (“IVF”) treatment. They subsequently launched Genelife, a lifestyle genetic testing and Umbilical Cord Wharton’s Jelly banking service.

  Cordlife Hong Kong and Healthbaby Hong Kong launched paediatric allergy testing to detect up to 104 allergens; bebegene®, a newborn genetic screening with comprehensive assessment of more than 120 genetic related diseases in infants and children aged 0-3; and LifeScreen, a talent genetic test panel for children.

  Cordlife Philippines celebrated the inauguration of new Cordlife satellite offices in St. Luke’s Medical Center Quezon City, Cebu City, and Davao City

  Stemlife Malaysia launched non-invasive prenatal testing in Malaysia.

• 2021

  Cordlife embarked on a digital transformation journey to change how the Group goes digital to better impact, externally for clients and internally for employees.

  Cordlife Singapore and Cordlife Hong Kong launched OptiQ, a first-of-its-kind corneal lenticule banking service.

  Cordlife Singapore partnered with SingHealth Duke-NUS Academic Medical Centre to advance stem cell technology to a first in-man clinical trial in Singapore. In addition, Cordlife Singapore also launched Moms Up, a one-stop solution app that provides localised advice on conceiving, pregnancy, and postpartum support for women in Singapore.

  Stemlife Malaysia received The BrandLaureate World’s e-Branding Award – Best Brand of the Year 2020 in Innovation Stem Cell Solutions, from The World Brands Foundation. Stemlife Malaysia also launched Bebegene, a newborn genetic screening service.

  Cordlife Hong Kong launched Cordlife Carrier Screening, Cordlife Hereditary Cancer Screening, Cordlife Hereditary Cardiac Disease Screening and Cordlife Hereditary Neurological Disease Screening.

  Cordlife Hong Kong and Cordlife Indonesia launched MIRA, a miRNA-based receptivity analysis testing to help couples undergoing IVF in determining the best time for embryo transfer to increase their chance of pregnancy.

  Cordlife Hong Kong, Cordlife Indonesia and Cordlife Philippines launched Cordlife Alliance, a community banking programme that allows Cordlife’s clients to help another Cordlife family in need of a cord blood unit.

  Cordlife India launched in-house diagnostic services.

  Cordlife India attained NABL accreditation for the first time